AXQ Capital LP Invests $693,000 in IQVIA Holdings Inc. (NYSE:IQV)

AXQ Capital LP acquired a new stake in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) during the 4th quarter, according to its most recent 13F filing with the SEC. The firm acquired 3,524 shares of the medical research company's stock, valued at approximately $693,000.

A number of other hedge funds have also recently bought and sold shares of IQV. Synergy Asset Management LLC bought a new position in shares of IQVIA during the fourth quarter valued at about $33,000. Avior Wealth Management LLC lifted its position in shares of IQVIA by 117.6% during the 3rd quarter. Avior Wealth Management LLC now owns 161 shares of the medical research company's stock worth $38,000 after buying an additional 87 shares in the last quarter. Lee Danner & Bass Inc. purchased a new position in shares of IQVIA in the 4th quarter worth approximately $44,000. Versant Capital Management Inc grew its holdings in shares of IQVIA by 46.0% in the fourth quarter. Versant Capital Management Inc now owns 295 shares of the medical research company's stock valued at $58,000 after acquiring an additional 93 shares in the last quarter. Finally, SBI Securities Co. Ltd. purchased a new stake in shares of IQVIA during the fourth quarter valued at approximately $60,000. 89.62% of the stock is owned by hedge funds and other institutional investors.

IQVIA Price Performance

NYSE IQV traded down $5.04 on Tuesday, hitting $181.07. The stock had a trading volume of 1,192,314 shares, compared to its average volume of 1,239,209. The firm has a 50-day moving average of $194.58 and a 200-day moving average of $207.73. The company has a market capitalization of $31.93 billion, a price-to-earnings ratio of 24.14, a price-to-earnings-growth ratio of 1.99 and a beta of 1.50. The company has a debt-to-equity ratio of 2.12, a quick ratio of 0.84 and a current ratio of 0.84. IQVIA Holdings Inc. has a 52-week low of $179.28 and a 52-week high of $254.54.

Remove Ads

IQVIA (NYSE:IQV - Get Free Report) last posted its quarterly earnings data on Thursday, February 6th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. Equities analysts expect that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on IQV shares. Truist Financial reaffirmed a "buy" rating and set a $263.00 target price (up from $261.00) on shares of IQVIA in a research report on Monday, February 10th. JPMorgan Chase & Co. lowered their price objective on shares of IQVIA from $240.00 to $232.00 and set an "overweight" rating on the stock in a research report on Tuesday, February 18th. Stephens started coverage on shares of IQVIA in a research note on Friday, December 20th. They issued an "overweight" rating and a $250.00 target price on the stock. William Blair reaffirmed an "outperform" rating on shares of IQVIA in a report on Wednesday, December 11th. Finally, Citigroup dropped their price objective on IQVIA from $225.00 to $210.00 and set a "neutral" rating on the stock in a research note on Tuesday, March 4th. Five investment analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $249.05.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.